Taiho to Acquire Araris in $1.14B Deal to Bolster Next-Gen ADC Pipeline
In a significant move to expand its oncology portfolio, Taiho Pharmaceutical Co., Ltd. has entered a definitive agreement to fully
Read moreIn a significant move to expand its oncology portfolio, Taiho Pharmaceutical Co., Ltd. has entered a definitive agreement to fully
Read moreCutting-edge CacoReady Cell-based Plates with pre-developed Caco-2 cells for in vitro permeability assessment have been a key tool in a
Read morePfizer announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS® (brentuximab vedotin) in combination with
Read moreNovel T Cell Staining Reagents Now Available at imusyn’s Web Shop imusyn is excited to announce the release of Dyemer
Read morePresident Donald Trump’s announcement of the $500 billion Stargate initiative marks a transformative moment for the pharmaceutical sector and healthcare
Read moreAstraZeneca’s Truqap (capivasertib) has achieved a significant milestone in the treatment of prostate cancer. Results from the CAPItello-281 Phase III
Read moreAOP Orphan Pharmaceuticals GmbH (AOP Health), in collaboration with Leukos Biotech, has reached a significant milestone in cancer therapy. The
Read moreThe 3-D Life RGD Peptide is a highly purified peptide designed specifically to enhance cell adhesion within 3-D hydrogel matrices.
Read moreCellendes GmbH is pleased to announce that its pioneering 3-D Life Hydrogel has been successfully utilised in a novel microfluidic
Read moreimusyn’s Dyemer & myDyemer are a pioneering class of ready-to-use and loadable T Cell staining reagents, developed for precise quantification
Read more